Litak 10 10 mg/ml. Solution for injection
PDF Leaflet Revision Date: 27 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
First line treatment for hairy cell leukaemia.
Dosage (summary)
0.14 mg/kg/day subcutaneously for 5 days or 0.10 mg/kg/day intravenously for 7 days.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to potential harm.
Key Drug Interactions
- Other myelosuppressive medicines
- Corticosteroids
Contraindications
- Hypersensitivity to cladribine
- Pregnancy and lactation
- Children under 18
- Moderate to severe renal impairment
- Moderate to severe hepatic impairment
Common side effects
- Myelosuppression
- Neutropenia
- Thrombocytopenia
- Anaemia
- Infections
Counselling Points
- Monitor for signs of infection and blood count changes.
- Avoid pregnancy during and for 6 months after treatment.
- Consider sperm cryoconservation for men prior to treatment.
Serious warnings
- Risk of myelosuppression and opportunistic infections
- Progressive multifocal leukoencephalopathy (PML)
- Secondary malignancies
Important Disclaimer
The Litak 10 10 mg/ml. Solution for injection professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
